BOTHELL, Wash. and ELMWOOD PARK, N.J., March 20 /PRNewswire-FirstCall/ --
Helix BioMedix, Inc. (OTC Bulletin Board: HXBM.OB), a developer of bioactive
peptides, and Grant Industries, a privately held developer, manufacturer and
marketer of cosmetic, textile, and performance specialty chemicals, today
announced the successful results of a human panel test for Grant's new
proprietary acne blend for use in over-the-counter acne products. The acne
solution, Granactive(TM), combines Helix BioMedix's proprietary Oligopeptide-
10 with salicylic acid and Grant's Invisiskin(TM), an ingredient used to
enhance delivery of bioactive compounds.
The panel test compared a formulation containing Granactive(TM) with
Oligopeptide-10 to a market leading benzoyl peroxide based product in treating
Grade 3 (moderate) or greater acne conditions. Results of the panel test
showed that treatment with Granactive(TM) was clearly superior in reducing the
number of comedone (non-inflammatory) lesions at each evaluation. In
addition, Granactive(TM) treatment resulted in significantly fewer comedones
after only 7 days of use indicating efficacy that was not only superior but
also more rapid. Counts of other lesion types associated with the condition
of acne (papules, pustules, and cysts) corroborated the comedone data.
Irritation decreased throughout the six week evaluation with both treatments,
and these scores were significantly reduced at days 28 and 42 with the
Granactive(TM) formulation.
Paul Granatell, Executive Director of Grant Industries, commented, "The
results of the human panel test of our new anti-acne blend which contains
Helix BioMedix's Oligopeptide-10 exceeded our expectations. The U.S. market
for anti-acne products sold over the counter is estimated at $488 million and
we believe there is a significant opportunity for product enhancements. At
Grant Industries, selling quality products and providing quality service to
our clients is key and we are very excited to market this new improved anti-
acne formulation to our cosmetic company customers. We also look forward to
continuing to work with Helix BioMedix to help address the growing demand for
value added ingredients."
R. Stephen Beatty, President and Chief Executive Officer of Helix
BioMedix, added, "We are very excited to be working with Grant Industries.
Grant has relationships with many major cosmetic companies and we see
significant opportunities for the incorporation of Oligopeptide-10, not only
in over-the-counter acne products, but in a range of skin care lines. As the
panel test demonstrated, the inclusion of Oligopeptide-10 in Grant's anti-acne
solution has produced a significant benefit. We look forward to bringing high
quality cosmetic ingredients to the marketplace in collaboration with Grant
and believe there is the potential to see products launched and revenues
received by Helix BioMedix before the end of 2006."
About Grant Industries
Grant Industries is a privately held company, located in Elmwood Park, NJ,
involved in the research, development, manufacturing, and marketing of
cosmetic, textile, and performance specialty chemicals. The company's
involvement in the textile industry dates back 60 years and four generations.
Grant offers the cosmetic industry a diversified product line of Gransil
silicone elastomer gels and powders, specialty materials and formulated
products. The company maintains manufacturing and warehousing in Elmwood
Park, NJ, Mexico, Dominican Republic, England, Korea, Japan, China, South
Africa and the European Union. More information about the company can be
found on the company's website at http://www.grantinc.com.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a portfolio
of issued patents that covers six distinct classes of peptides, including over
100,000 unique peptide sequences. The company's mission is to become the
industry leader in developing and commercializing small proteins known as
bioactive peptides. The antimicrobial and wound healing properties of these
peptides qualify them for inclusion in a wide range of both pharmaceutical and
consumer products. The company is currently focused on the development of
selected peptides as topical anti-infectives and in wound healing. Non-
pharmaceutical applications being pursued by Helix BioMedix include adjuvants
for cosmetics/cosmeceuticals, personal care, plant health, animal health and
wide-spectrum biocides. More information about the company and its proprietary
peptides can be found on the company's website at http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements which
are not historical facts) within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements involve risks
and uncertainties, including activities, events or developments that the
company expects, believes or anticipates will or may occur in the future. A
number of factors could cause actual results to differ from those indicated in
the forward-looking statements, including Helix BioMedix's ability to
successfully raise additional capital, enter into revenue generating license
agreements, continue its research and development efforts, including pre-
clinical and clinical studies, and general economic conditions. Additional
assumptions, risks and uncertainties are described in detail in our reports
and other filings with the Securities and Exchange Commission. Such filings
are available on our website or at http://www.sec.gov. Readers are cautioned that
such forward-looking statements are not guarantees of future performance and
that actual results or developments may differ materially from those set forth
in the forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact:
Helix BioMedix, Inc.
David H. Kirske, 425-402-8400
dkirske@helixbiomedix.com
or:
Grant Industries, Inc.
Paul Granatell, 201-791-8700
pgranatell@grantinc.com
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
http://www.grantinc.com
CONTACT:
David H. Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, dkirske@helixbiomedix.com; Paul Granatell of
Grant Industries, Inc., +1-201-791-8700, pgranatell@grantinc.com;
or Investor Relations: Alison Ziegler of Cameron Associates,
+1-212-554-5469, alison@cameronassoc.com
|
